Table 1.
Characteristics of experimental animals after 2 weeks of treatment with ET receptor antagonists
| Characteristics | HbAA | HbSS | ||||
|---|---|---|---|---|---|---|
| Vehicle | Ambrisentan | A-182086 | Vehicle | Ambrisentan | A-182086 | |
| Body weight, g | M: 25.7±1.2 | M: 28.8±0.8 | M: 26.8±0.4 | M: 27.5±1.1 | M: 27.5±0.8 | M: 28.2±0.5 |
| F: 22.3±1.0 | F: 21.7±0.5 | F: 21.7±0.7 | F: 21.9±1.0 | F: 21.1±0.9 | F: 23.0±0.4 | |
| Right kidney/body weight, mg/g | 6.6±0.3 | 6.5±0.4 | 6.3±0.4 | 7.4±0.4 | 7.6±0.5 | 7.8±0.5 |
| Left kidney/body weight, mg/g | 6.2±0.3 | 5.8±0.3 | 5.9±0.3 | 7.2±0.4 | 7.7±0.5 | 7.0±0.4 |
| Spleen/body weight ratio, % | 0.9±0.1 | 0.8±0.1 | 0.9±0.1 | 6.9±0.3a | 5.7±0.3a,b | 7.0±0.5a |
| Water intake, ml/24 h | 3.2±0.3 | 4.7±0.5 | 4.6±0.6 | 5.2±0.5 | 6.0±0.5 | 5.8±0.5 |
| Urine excretion, ml/24 h | 1.0±0.2 | 1.3±0.1 | 1.6±0.3 | 2.1±0.3a | 2.3±0.4a | 2.7±0.3a |
| Urine osmolality, mOsm/kg | 2482±147 | 2299±121 | 2601±121 | 1177±135a | 1551±174a | 1624±80a |
| Systolic BP, mmHg | 120±1 | 119±2 | 121±1 | 123±1 | 119±3 | 122±2 |
| Serum creatinine, mg/dl | 0.09±0.01 | 0.10±0.01 | 0.12±0.01 | 0.11±0.01 | 0.11±0.01 | 0.09±0.01 |
Data are means±SEM (n=12–14 in HbSS groups and n=6–9 in HbAA groups). M, male; F, female.
a
P<0.05 versus HbAA vehicle.
b
P<0.05 versus HbSS vehicle.